CNSPHIGH SIGNALOPERATIONAL10-K

CNSP has undergone a complete strategic pivot from a clinical pharmaceutical company focused on brain tumor treatments to a broader biotechnology company targeting neurology and oncology with significantly deteriorated financial position.

This represents a fundamental transformation of the company's business model, moving away from specific drug candidates (TPI 287 and Berubicin) and licensing partnerships with Cortice Biosciences and Reata Pharmaceuticals to a broader, less defined therapeutic approach. The shift suggests either previous programs failed or were abandoned, creating uncertainty about the company's pipeline and competitive positioning in the new strategic direction.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The company shows mixed financial signals with improved operating cash flow burn (-$17.1M to -$13.8M) but concerning balance sheet deterioration including a 62.5% surge in liabilities to $4.1M and a 26.8% decline in stockholders' equity to $4.5M. Despite maintaining cash levels at $7.2M, the doubling of interest expense and substantial increase in current liabilities suggests mounting financial pressure that could challenge the company's ability to execute its new strategic direction.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+334%
$4K→$18K

Capital expenditure jumped 334% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
+96.5%
$7K→$14K

Interest expense surged 96.5% — significant debt increase or rising rates materially impacting earnings.

Total Liabilities
Balance Sheet
+62.5%
$2.5M→$4.1M

Liabilities grew 62.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+62.5%
$2.5M→$4.1M

Current liabilities surged 62.5% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-26.8%
$6.2M→$4.5M

Equity decreased 26.8% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Cash Flow
Cash Flow
+19.3%
-$17.1M→-$13.8M

Operating cash flow grew 19.3% — strong conversion of earnings to cash, healthy business fundamentals.

Cash & Equivalents
Balance Sheet
+11.4%
$6.5M→$7.2M

Cash grew 11.4% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 33 ITEM 7A.
( CNS, the Company, we, us, or our ) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology.
Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need.
Significant progress has been made in the biological and molecular understanding of these diseases, enabling a shift to high-value disease-modifying therapies and precision medicine approaches.
Together with advancements in diagnostic capabilities to aid in patient selection, there is the potential to improve the probability of success and reduce development timelines.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 ITEM 7A.
Overview We are a clinical pharmaceutical company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors, based on intellectual property that we license under license agreements with Cortice Biosciences, Inc.
( Cortice ) and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc.
We believe our drug candidates, TPI 287 and Berubicin, may be significant developments in the treatment of Glioblastoma and other CNS malignancies, and if approved by the U.S.
Food and Drug Administration ( FDA ), could give Glioblastoma patients important new therapeutic alternatives to the current standard of care.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →